Biomarker name | Cancer type | Tissue detected |
---|---|---|
Risk | Â | Â |
BRCA1 DNAm signature (1,829 CpGs) | Breast | Whole blood DNA [65] |
140 variable CpGs | Cervical | Normal uterine cervix cells [58] |
Diagnosis | Â | Â |
GSTP1 | Prostate | Serum, urine, ejaculate [70] |
APC, EDNRB, GSTP1 | Prostate | Urine [71] |
CDKN2A, ARF, MGMT, GSTP1 | Prostate | Urine [72] |
GSTP1, APC, PTGS2 | Prostate | Paraffin-embedded tissues [110] |
SETP9 | Colorectal | Blood plasma [77] |
APC, MGMT, RASSF2A, WIF1 | Colorectal | Blood plasma [78] |
SHOX2 | NSCLC | Bronchial fluid aspirates/ blood plasma [76] |
CDKN2A, MGMT | NSCLC | Sputum [74] |
CCND2, RASSF1A, APC, HIN1 | Breast | Fine needle aspiration biopsy [111] |
ZNF154, HOXA9, POU4F2, EOMES | Bladder | Urine [112] |
Prognosis | Â | Â |
20-gene signature | ALL | Leukemic cells from bone marrow and peripheral blood [88] |
15-gene classifier | AML | Â |
RASSF1A, APC | Breast | Serum [82] |
ZAP70 | CLL | CD19 sorted mononuclear cells [80] |
CDKN2A | CCR | Blood plasma [81] |
DAPK1 | Head and neck | Tumor samples [84] |
DAPK1 | NSCLC | Tumor samples [83] |
CDKN2A, RASSF1A, CDH13, APC | NSCLC | Primary tumors and lymph nodes [85] |
HIST1H4F, PCDHGB6, NPBWR1, ALX1, HOX9 | NSCLC | Tumor samples [89] |
ALDH1A, OSR2, GATA4, GRIA4, IRX4 | OPSCC | Tumor samples [59] |
GSTP1, APC, PTGS2 | Prostate | Tumor samples [110] |
Response to therapy | Â | Â |
BRCA1 | Breast | |
BCL2 | Breast | Tumor samples [113] |
PITX2 | Breast | Tumor samples [114] |
TFAP2E | Colon | Tumor samples [115] |
MGMT | Glioma | |
APAF1 | Melanoma | Tumor samples/cell lines [116] |
IGFBP3 | NSCLC | Tumor samples/cell lines [117] |
BRCA1 | Ovary | Tumor samples [94] |